2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
2
Virus Diseases
1
Tumor Virus Infections
1
Recurrence
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers
1
Laryngeal Diseases
1
Hypoxia
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
10
Cisplatin
9
Cetuximab
9
Paclitaxel
5
Radiotherapy
4
Nivolumab
4
Fluorouracil
4
zalutumumab
3
Docetaxel
3
Taxes
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Gefitinib
2
Cyclophosphamide
2
Carboplatin
2
temsirolimus
1
sintilimab
1
poly ICLC
1
osimertinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
cobimetinib
1
atezolizumab
1
advexin
1
abemaciclib
1
Vorinostat
1
Sorafenib
1
Risk Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
Nimorazole
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled